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Background/Purpose: Adalimumab is a fully humanized monoclonal antibody that blocks tumor necro-
sis factor (TNF)-α, which is effective in the treatment of patients with rheumatoid arthritis (RA). The pur-
pose of this study was to compare the efficacy and safety of adalimumab plus methotrexate (MTX) and
MTX alone in Taiwanese patients with active RA.
Methods: Forty-seven patients with active RA who were maintained on MTX therapy at a stable dose of
10–15 mg/week for 4 weeks were randomized blindly to receive adalimumab 40 mg (n = 35) or placebo
(n = 12) by subcutaneous injection every other week over a period of 12 weeks. The primary endpoint was
a reduction in tender and swollen joint counts of 20% (ACR20), 50% (ACR50) and 70% (ACR70), as de-
termined by the American College of Rheumatology criteria in week 12. The occurrence of treatment-
emergent adverse events (TEAEs) was the primary safety variable.
Results: Addition of adalimumab to MTX resulted in a significant reduction in the number of swollen
joints (12.6 vs. 5.6; p = 0.011), patients’ global assessment of disease activity (18.0 vs. 4.8; p = 0.040), pain
visual analog scale (18.3 vs. 1.3; p = 0.015), and disability indices of the Health Assessment Questionnaire
(0.6 vs. 0.2; p = 0.031), compared with MTX alone after 12 weeks of therapy. Overall improvement in dis-
ease activity was assessed by ACR20 (54.3% vs. 33.3%), ACR50 (34.3% vs. 16.7%) and ACR70 (14.3% vs.
0%), and all favored the adalimumab plus MTX group. TEAEs were comparable between the treatment
groups, except for a slightly higher incidence of severe infection in the adalimumab plus MTX group.
Conclusion: Adalimumab in combination with MTX is well tolerated and provides significantly more
clinical benefits than MTX alone in Taiwanese patients with active RA. [J Formos Med Assoc 2009;108(4):
310–319]
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Rheumatoid arthritis (RA) is characterized by a
progressive inflammatory synovitis, and should
be treated early and aggressively to prevent joint
destruction and disability.1,2 Although disease-
modifying antirheumatic drugs (DMARDs) can
inhibit disease progression, many patients fail to
achieve an adequate or sustained response to
therapy because of lack of efficacy or toxicity.3
Among the DMARDs used to treat RA, metho-
trexate (MTX) is the agent of choice because of
its early onset of action and superior efficacy and
tolerability.4 However, many patients with RA ex-
hibit continued radiographic progression despite
receiving therapeutic doses of MTX.5
Tumor necrosis factor (TNF)-α is a crucial in-
flammatory mediator in rheumatoid synovitis
and subsequent tissue damage in RA, and there-
fore represents a promising target for therapeutic
intervention in this disease.6,7 Clinical and phar-
macological studies have shown that TNF-α in-
hibitors can be effective and well-tolerated in RA
patients.8–10 Adalimumab (Humira; Abbott Labo-
ratories, Abbott Park, IL, USA), the first fully hu-
manized anti-TNF-α monoclonal antibody for RA
treatment, has been shown to be effective in the
treatment of RA patients.11 Furthermore, adali-
mumab therapy is superior to MTX alone in re-
ducing disease activity, arresting structural damage,
and decreasing disability over 2 years in RA 
patients.10–12 In December 2002, adalimumab
was approved in the USA for reducing signs and
symptoms and inhibiting progression of structural
damage in adults with moderately to severely 
active RA, who had an inadequate response to
one or more DMARDs. MTX can act synergisti-
cally with anti-TNF-α inhibitors; therefore, adali-
mumab in combination with MTX reduces
disease activity, inhibits radiographic progression,
and improves function more effectively than either
adalimumab or MTX monotherapy.13 Although
combination therapy with anti-TNF-α and MTX
increases direct costs, adalimumab and MTX ther-
apy reduced job loss and improved productivity
in RA patients when compared with MTX mono-
therapy, which suggests that combination therapy
is indeed cost-effective.14
The present study is believed to be the first
double-blind study to compare the efficacy and
safety of adalimumab plus MTX with placebo plus
MTX in Taiwanese patients with active RA.
Methods
Patients
The present study was conducted at Taichung
Veterans General Hospital in Taiwan. Forty-seven
patients (37 female, 10 male; median age, 53.0
years; age range, 29.0–75.0 years) who fulfilled
the American College of Rheumatology (ACR)
1987 revised criteria for RA,15 and with a disease
duration of more than 1 year were enrolled. Active
disease was defined as having more than six
swollen joints and nine tender joints for at least
3 months. Disease activity for each RA patient
was also assessed by the 28-joint disease activity
score (DAS28).16 Those who had been receiving
MTX at a stable dose of 10–15 mg weekly and had
been washed clean from other DMARDs for at
least 4 weeks prior to entry were considered eligi-
ble for participation in this study. Patients were
excluded if they had received any of the follow-
ing: TNF-α inhibitors including adalimumab;
alkylating agents such as chlorambucil or cyclo-
phosphamide; investigational biological agents
including anti-CD4 antibody; other investiga-
tional agents within 30 days; or live vaccine within
3 months prior to study. Other criteria for exclu-
sion were as follows: patients with clinically ac-
tive tuberculosis (TB) or radiographic evidence
of old pulmonary TB; patients with renal (serum
creatinine > 1.5 mg/dL) and hepatic impairment
(alanine aminotransferase, aspartate transami-
nase values > 2 times the upper limit of normal
range); total bilirubin level >3 mg/dL; hemoglobin
< 9.5 mg/dL for men and < 9.0 mg/dL for women;
platelet count < 150,000/mm3; white blood cell
count < 3000 cells/mm3; pregnant and nursing
mothers; patients with a history of alcohol and
drug abuse; patients with positive serology for
human immunodeficiency virus antibody, hepa-
titis B surface antigen or hepatitis C antibody;
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history of another collagen–vascular disease; pre-
existing or recent onset of central nervous system
demyelinating disorders; patients with significant
medical diseases including uncompensated con-
gestive heart failure, severe myocardial infarction
within 1 year, uncontrolled hypertension, poorly
controlled diabetes mellitus, and chronic or active
infection; and patients with any condition that
might cause their participation in this study to be
detrimental, as judged by a physician. In addition,
concomitant use of hydroxychloroquine, sulfasa-
lazine, azathioprine, cyclophosphamide, minocy-
cline, mycophenolate mofetil, other DMARDs or
any other investigational drug was prohibited
during this study. However, nonsteroidal anti-
inflammatory drugs, oral corticosteroids, MTX,
and aspirin concomitantly used during the study
were allowed as long as the dose was maintained
throughout the study. The Clinical Research Ethics
Committee at Taichung Veterans General Hospital
approved the study protocol, and informed con-
sent was obtained from each participant.
Study design
In this double-blind study, 47 patients were ran-
domly assigned in a 3:1 ratio to receive either
adalimumab 40 mg or placebo by subcutaneous
injection every other week, while continuing to
receive MTX over a period of 12 weeks. Data on
demographic characteristics, contact history with
subjects with active TB disease, medical history,
and prior medications were collected. Body weight
and height were measured, physical examination
was performed, and vital signs including blood
pressure and heart rate were taken. Laboratory ex-
aminations including hematology, blood chem-
istry, C-reactive protein (CRP), rheumatoid factor,
hepatitis B surface antigen, hepatitis C antibody,
urinalysis, and pregnancy test in women were per-
formed during a fasting state. A complete joint
assessment (68-joint version) was performed for
detection of a tender joint count, swollen joint
count, and duration of morning stiffness, which
were recorded by an experienced rheumatologist
who was blinded to the results of other evaluations.
Each patient underwent chest X-ray and 12-lead
electrocardiography. Initially, all patients under-
went a 4-week washout period prior to commence-
ment of treatment with trial medications. After the
washout period, baseline laboratory data were
checked to determine eligibility for participation.
In addition, all patients received baseline TB
screening using tuberculin skin test (TST) ac-
cording to the Mantoux method (intradermal in-
jection of 2 tuberculin units of PPD RT-23).17
The two-step TST was not performed in any of
our patients at baseline screening. The size of 
induration was measured 48–72 hours later, and
a positive result was defined as an induration 
diameter ≥ 5 mm.18 Patients who had positive TST
received prophylaxis with isoniazid 300 mg/day
4 weeks before starting trial medications.
Efficacy and safety evaluation
Efficacy and safety evaluations were performed at
monthly intervals. Patients were assessed for the
primary efficacy endpoint [the ACR20 response
at week 12 in the modified full analysis set,19 and
a subject was defined as a responder if the follow-
ing three criteria were met: ≥ 20% improvement in
tender joint count; ≥20% improvement in swollen
joint count; and ≥ 20% improvement in at least
three of the following assessments: pain visual
analog scale (VAS; 0, no pain and 100, severe pain);
patient’s global assessment of disease activity (0,
no disease activity and 10, extreme disease activity);
physician’s global assessment of disease activity
(0, no disease activity and 10, extreme disease ac-
tivity); the disability index of Health Assessment
Questionnaire (HAQ; 0, without difficulty; 1, with
some difficulty; 2, with much difficulty; and 3,
unable to do so),20 and CRP values]. Secondary
efficacy variables included the following: ACR50
and ACR70 responses19 at week 12, change from
baseline in the individual components of the ACR
response at week 12, and change from baseline in
the presence/absence and duration of morning
stiffness at week 12. ACR20 is defined as a reduc-
tion in tender and swollen joint counts of 20%,
ACR50 of 50% and ACR70 of 70%, from baseline.
Monitoring of vital signs, physical examina-
tions, laboratory parameters (hematology, blood
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chemistry, CRP, routine urinalysis), and adverse
events (AEs) was performed every month for safety
evaluation. The occurrence of treatment-emergent
adverse events (TEAEs) was the primary safety
variable.
Statistical analysis
The efficacy analysis was performed on an “intent-
to-treat (ITT)” population, which was defined as
all patients with baseline data and at least one post-
treatment evaluation. The last observation carried
forward (LOCF) method was used to substitute for
missing data. Primary and secondary efficacy vari-
ables were analyzed by calculating the change
and percentage change from baseline at weeks 4,
8 and 12 (endpoint). The change and percentage
change from baseline in the treatment group were
determined by nonparametric Wilcoxon signed
rank test. The differences between treatment groups
for the efficacy endpoints were compared by non-
parametric Wilcoxon rank sum test. The differ-
ences in the ACR 20%, 50%, and 70% response
rate were analyzed by Fisher’s exact test.
The safety analysis was performed on all pa-
tients who received randomized study medica-
tion. TEAEs included all AEs that either began on
or after administration of study drugs, or pre-
existing conditions that worsened on or after study
drug administration. The number and percent-
age of subjects reporting TEAEs were tabulated
by MedDRA21 preferred terms and system organ
class. Vital signs and laboratory data profiles
were analyzed based on change from baseline
using nonparametric Wilcoxon rank sum test for
the analysis between treatment groups, and
Wilcoxon signed rank test for the analysis within
treatment groups. The number of patients with
AEs was compared between treatment groups
using Fisher’s exact test.
Results
Demographics and baseline characteristics
Forty-seven RA patients who were enrolled in the
ITT population were randomized into treatment
groups (35 in the adalimumab plus MTX group
and 12 in the MTX alone group). As illustrated in
Table 1, demographics were comparable between
the two treatment groups. The majority of the
subjects in both treatment groups were female
(placebo, 91.7%; adalimumab, 74.3%). The mean
age was 53.2 years for subjects in the placebo treat-
ment group and 52.9 years in the adalimumab
group. All RA patients had active disease (me-
dian DAS28, 6.54; range, 5.63–7.37). There was
no significant difference in baseline characteris-
tics including values for body mass index, radio-
graphic staging, the proportion of extra-articular
features including Sjögren’s syndrome, baseline
assessment of disease activity, disability index of
the HAQ, positive rate of serum rheumatoid factor,
baseline chemistry values, dosage of corticosteroids,
or the number of previously used DMARDs be-
tween the placebo and adalimumab treatment
groups. Before starting therapy with study med-
ications, two (16.7%) placebo and seven (20.0%)
adalimumab-treated subjects gave positive TST
results.
Efficacy assessment: ACR20, ACR50 and
ACR70 response
The mean values for the primary and secondary
efficacy variables in the ITT population are shown
in Table 2. The primary efficacy endpoints, which
were the reduction in the number of swollen
joints from baseline, were significantly greater in
the adalimumab-treated than in the placebo-
treated group (12.6 vs. 5.6; p < 0.05) after 12 weeks
of therapy. Patient’s global assessment showed
significantly greater reduction in the severity of
disease activity after 12 weeks of therapy in the
adalimumab-treated than in the placebo-treated
group (−18.0 vs. −4.8; p < 0.05). The baseline 
VAS scores for pain in both groups were compa-
rable (67.0 mm in the adalimumab-treated and
60.0 mm in the placebo-treated group), but were
reduced by 28% in the adalimumab-treated group
and increased by 2.2% in the placebo-treated
group after 12 weeks of therapy. Performance of
daily activity assessed by the disability index of
HAQ showed significantly more improvement 
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in the adalimumab-treated than in the placebo-
treated group (−0.6 vs. −0.2; p < 0.05). A summary
of ACR20, ACR50 and ACR70 response rates at
week 12 for the ITT population is included in
Table 3. As shown in the Figure, the highest per-
centage of adalimumab-treated subjects achieved
an ACR20 response for the first time at week 8
during the 12-week treatment period. After 12
weeks of treatment, four subjects (33.3%) in the
placebo group and 19 (54.3%) in the adalimumab
group achieved an ACR20 response. Although
the difference between treatment groups in the
proportion of ACR20 responders was not statisti-
cally significant (p = 0.318), there was a strong
trend towards a superior ACR20 response rate in
the adalimumab group compared to the placebo
group. Following 12 weeks of treatment, 12
(34.3%) adalimumab-treated subjects achieved
Table 1. Demographic data and baseline characteristics of patients with rheumatoid arthritis separated by
treatment groups*
Parameter Adalimumab plus MTX (n = 35) MTX alone (n = 12)
Age (yr) 53.0 (29.0–75.0) 53.0 (35.0–73.0)
Female 26 (74.3) 11 (91.7)
Duration of RA (yr) 6.2 (0.3–19.1) 8.3 (1.3–15.6)
BMI (kg/m2) 23.4 (17.9–37.3) 24.1 (19.0–34.5)
RF-positive 30 (85.7) 11 (91.7)
RF level (IU/mL) 135 (13.8–3470) 257 (13.6–3110)
MS duration (min) 120 (0–420) 195 (0–420)
DAS28 6.41 ± 0.33 6.54 ± 0.42
Positive TST results 7 (20.0) 2 (16.7)
Previously used DMARDs
MTX 35 (100) 12 (100)
Sulfasalazine 33 (94.3) 11 (91.7)
Hydroxychloroquine 22 (62.9) 7 (58.3)
Cyclosporin 17 (48.6) 9 (75.0)
*Data presented as median (range) or n (%) or mean ± standard deviation. MTX = methotrexate; RA = rheumatoid arthritis; BMI =
body mass index; RF = rheumatoid factor; MS = morning stiffness; DAS28 = 28-joint disease activity score; TST = tuberculin skin test;
DMARDs = disease-modifying antirheumatic drugs.
Table 2. Components of American College of Rheumatology response*
Adalimumab plus MTX (n = 35) MTX alone (n = 12)
Parameter
Baseline 12 wk Baseline 12 wk
TJC 32.5 (28.6–36.3) 18.6 (13.7–23.6) 37.2 (26.1–48.2) 27.8 (14.7–41.0)
SJC 21.9 (18.8–24.9) 9.3 (6.0–12.6)† 24.1 (19.2–29.0) 18.5 (9.4–27.6)
Pain VAS (mm) 66.5 (60.8–72.1) 48.1 (40.9–55.4)† 60.0 (50.8–69.2) 61.3 (50.4–72.1)
Patient’s GA 72.4 (67.3–77.5) 54.4 (46.8–62.0)† 70.9 (63.5–78.3) 66.2 (54.7–77.7)
Physician’s GA 81.0 (77.1–84.9) 40.7 (32.1–49.3) 82.4 (76.2–88.6) 56.3 (38.2–74.3)
Disability index, HAQ‡ 1.7 (11.5–1.9) 1.1 (0.8–1.4)† 1.8 (1.5–2.1) 1.6 (1.1–2.2)
CRP (mg/L) 2.0 (1.2–2.9) 1.4 (0.3–2.5) 2.4 (1.0–3.9) 2.3 (0.8–3.8)
*Data presented as mean (95% confidence interval); †p < 0.05, adalimumab/MTX vs. placebo/MTX, based on change from baseline;
‡HAQ (Health Assessment Questionnaire) includes four categories: dressing and grooming, arising, eating, and walking, on a 0–3 scale
(0, best; 3, worst). MTX = methotrexate; TJC = tender joint count; SJC = swollen joint count; VAS = 0–100-mm visual analog scale 
(0, best; 100, worst); GA = global assessment of disease activity, on a 0–100 scale (0, best; 100, worst); CRP = C-reactive protein.
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Figure. Percentage of patients with rheumatoid arthritis
who met the American College of Rheumatology (ACR)
criteria for 20%, 50% and 70% improvement (ACR20,
ACR50, and ACR70, respectively) during treatment with
methotrexate (MTX) plus either placebo or adalimumab
administered subcutaneously every other week.
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an ACR50 response compared to two (16.7%)
placebo-treated subjects. Similarly, following 12
weeks of treatment, five (14.3%) adalimumab-
treated subjects achieved an ACR70 response com-
pared to no placebo-treated subjects. However,
these differences were not statistically significant
since this exploratory study was not powered to
detect statistically significant differences between
treatment groups.
Occurrence of TEAEs
AEs, irrespective of relationship to study drugs,
were reported more frequently in the placebo
group (91.7%) than in the adalimumab group
(80.0%, Table 4). The incidence of AEs considered
to be possibly related to study drugs was similar
in both treatment groups (16.7%, placebo; 20.0%,
adalimumab). The most commonly reported AE
was upper respiratory tract infection, which was
reported at similar rates in both treatment groups
(33.3%, placebo; 37.1%, adalimumab). There were
slightly higher percentages of subjects reporting
herpes simplex (8.6%) in the adalimumab group
than in the placebo group (0%). Abnormal liver
function tests, which were reported at a higher in-
cidence in the adalimumab group (14.3%) than
the placebo group (0%), were judged by the in-
vestigators as probably not related to study drugs,
and returned to normal while the study continued.
Injection-site reactions (ISRs) occurred in only one
patient (2.9%) in the adalimumab group. Evalua-
tion of laboratory changes, including antinuclear
Table 3. Patients with ACR20, ACR50, and ACR70
at week 12*
Response Adalimumab plus MTX alone 
p†
criteria met MTX (n = 35) (n = 12)
ACR20 19 (54.3) 4 (33.3) 0.318
ACR50 12 (34.3) 2 (16.7) 0.302
ACR70 5 (14.3) 0 (0.0) 0.309
*Values are the number (%) of patients who met the American
College of Rheumatology criteria for 20%, 50% and 70% im-
provement (ACR20, ACR50, and ACR70, respectively) at week 12
(patients who did not complete the 12-week study were defined as
non-responders); †adalimumab plus MTX vs. MTX alone, based
on Fisher’s exact test. MTX = methotrexate.
Placebo plus MTX
Adalimumab plus MTX
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antibodies and anti-dsDNA antibodies, did not
demonstrate any clinically relevant differences
between the two treatment groups.
Relatively few TEAEs were reported in either
treatment group. Severe AEs were reported in
14.3% of adalimumab-treated subjects compared
to 8.3% of placebo-treated subjects, and AEs
leading to discontinuation occurred in 8.6% of
adalimumab-treated subjects compared to none
of the placebo-treated subjects. Of the six severe
AEs reported in the adalimumab group, three
were of infectious etiology (1 case of TB, 1 of pneu-
monia, 1 of sinusitis). The patient (63-year-old
man) with a baseline TST-negative result devel-
oped TB pleurisy after 6 weeks of adalimumab
therapy, but completely recovered with appropri-
ate anti-TB therapy. However, none of seven RA
patients in the adalimumab-treated group with
TST-positive results, who received isoniazid pro-
phylaxis (INHP) 1 month before starting study
medications, developed active TB. A 49-year-old
woman in the adalimumab-treated group devel-
oped bacterial pneumonia after 8 weeks of therapy,
but improved after parenteral antibiotic therapy.
No deaths, immunological reactions or malignan-
cies were reported during the study.
Discussion
Adalimumab acts by binding TNF-α, which 
is known to play a pivotal role in the pathogen-
esis of RA.6,7 Consistent with previous clinical 
trials,10–13 the present study showed that adali-
mumab in combination with MTX was well tol-
erated and significantly more effective than MTX
alone in Taiwanese patients with RA. During the
12-week treatment period, signs and symptoms
of RA were relieved as early as 4 weeks and the
highest percentage (20%) of adalimumab-treated
subjects achieved an ACR20 response for the first
time at week 8. In addition, more subjects in the
adalimumab group achieved ACR20, ACR50 and
ACR70 responses compared with those in the
placebo group after 12 weeks of treatment, al-
though these differences were not statistically
significant in this exploratory study. The ACR re-
sponse criteria, however, are only a relative mea-
sure and are not necessarily a realistic tool for the
definition of therapeutic success.22 The ACR 
response rate of adalimumab-treated patients
was lower in the present study than the rate ob-
served in other studies.11,13 This disparity may
have resulted from the differences in the sample
Table 4. Treatment-emergent adverse events observed in patients with rheumatoid arthritis by treatment
groups*
Adalimumab plus MTX (n = 35) MTX alone (n = 12)
Any adverse event 28 (80.0) 11 (91.7)
Upper respiratory tract infection 13 (37.1) 4 (33.3)
Abnormal liver function test 5 (14.3) 0
Skin lesion (non-infectious) 4 (11.4) 2 (16.7)
Herpes simplex 3 (8.6) 0
Constipation 2 (5.7) 0
Pneumonia 1 (2.9) 0
Tuberculosis 1 (2.9) 0
Sinusitis 1 (2.9) 0
Injection-site reaction 1 (2.9) 0
Abdominal pain 1 (2.9) 1 (8.3)
Gastritis 1 (2.9) 1 (8.3)
Hyperlipidemia 1 (2.9) 1 (8.3)
Mouth ulceration 0 1 (8.3)
Urinary tract infection 0 1 (8.3)
*Data presented as n (%).
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size and in the duration of adalimumab therapy
(12 weeks in our study vs. 24 weeks in other
studies).
There were no differences in the incidence 
of AEs between the adalimumab- and placebo-
treated groups. The most commonly reported AE
in both treatment groups was upper respiratory
tract infection, which was reported at similar rates
in both treatment groups. Although in previous
controlled studies, ISRs occurred significantly
more often and were reported in up to 10.6% of
adalimumab-treated patients,12 only one patient
(2.9%) in our adalimumab-treated group devel-
oped an ISR. Relatively few TEAEs, severe AEs,
AEs leading to discontinuation, and serious in-
fectious AEs were reported in either treatment
group; however, there was a higher incidence of
serious infections in the adalimumab group than
in the placebo group. All three subjects reporting
serious infections were receiving concomitant cor-
ticosteroids and MTX 12.5–15 mg weekly. As the
mechanism of action of TNF antagonists such as
adalimumab is the inhibition of an immunolog-
ically active cytokine, such combination therapy
may increase the risk of developing a serious in-
fection and therefore, subjects on combination
immunosuppressive therapy need to be closely
monitored for any signs of infection, and treated
appropriately.
Even with universal implementation of Bacillus
Calmette–Guérin vaccination for newborn babies
in Taiwan, TB was still prevalent at a notification
rate of 74.6/100,000 people in 2002.23 RA patients
often have compromised immune function as 
a result of underlying disease, increased age, 
comorbidity, and the use of immunosuppressive
agents, and an increased risk of active TB disease
has also been reported.24–26 As TNF-α has an im-
portant role in the host defense against Mycobac-
terium tuberculosis, including granuloma formation
and containment of TB,27 TNF-α inhibitor ther-
apy has been found to be associated with an 
increased TB risk.28–30 In Spain, a 12–20-fold in-
crease in risk associated with TNF-α inhibitor
therapy has been reported.30 As noted, active TB
in RA patients receiving TNF-α inhibitors mainly
appears to be caused by reactivation of latent TB
infection (LTBI).31 Recent studies have shown
that adequate screening for LTBI prior to anti-
TNF therapy, and INHP can effectively prevent
the occurrence of active TB disease.32–34 One pa-
tient with a baseline TST-negative result in our
study developed active extrapulmonary TB after
6 weeks of adalimumab therapy. The TST anergy
in this patient may have been caused by the use
of immunosuppressive agents and immune dys-
function related to RA.35 However, none of seven
RA patients in the adalimumab-treated group with
TST-positive results who received INHP 1 month
before starting study medications developed active
TB. Our results were consistent with those of pre-
vious reports that indicated the efficacy of INHP
in preventing reactivation of LTBI.32–33,36
In conclusion, adalimumab was generally safe
and well-tolerated in most subjects when given
for up to 12 weeks. The adalimumab-treated
group had a slightly increased risk of serious in-
fection. Therefore, subjects need to be monitored
for signs of infection during treatment and should
also be evaluated for the possibility of LTBI before
initiation of treatment. This study demonstrated
that treatment of Taiwanese RA patients with
adalimumab has a favorable risk-benefit ratio.
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